BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

$141.99 +2.49 (+1.78 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$139.50
Today's Range$139.09 - $142.14
52-Week Range$98.22 - $143.64
Volume166,253 shs
Average Volume188,415 shs
Market Capitalization$5.23 billion
P/E Ratio46.55
Dividend Yield0.92%
Beta0.78

About BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Debt-to-Equity Ratio0.36%
Current Ratio3.10%
Quick Ratio2.49%

Price-To-Earnings

Trailing P/E Ratio46.5542509975443
Forward P/E Ratio35.50
P/E Growth2.55

Sales & Book Value

Annual Sales$563 million
Price / Sales9.45
Cash Flow$5.13 per share
Price / Cash27.66
Book Value$26.63 per share
Price / Book5.33

Profitability

Trailing EPS$3.05
Net Income$76.08 million
Net Margins19.17%
Return on Equity14.39%
Return on Assets8.89%

Miscellaneous

Employees1,800
Outstanding Shares37,470,000

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE announced a quarterly dividend on Wednesday, February 7th. Stockholders of record on Friday, February 16th will be paid a dividend of $0.32 per share on Friday, March 2nd. This represents a $1.28 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, February 15th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, February, 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.10. The biotechnology company had revenue of $154.15 million for the quarter, compared to the consensus estimate of $145.93 million. BIO-TECHNE had a net margin of 19.17% and a return on equity of 14.39%. The firm's quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 earnings per share. View BIO-TECHNE's Earnings History.

When will BIO-TECHNE make its next earnings announcement?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for BIO-TECHNE.

Where is BIO-TECHNE's stock going? Where will BIO-TECHNE's stock price be in 2018?

7 analysts have issued twelve-month target prices for BIO-TECHNE's shares. Their predictions range from $115.00 to $160.00. On average, they expect BIO-TECHNE's stock price to reach $144.25 in the next twelve months. View Analyst Ratings for BIO-TECHNE.

Who are some of BIO-TECHNE's key competitors?

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:

  • Robert V. Baumgartner CPA, Independent Chairman of the Board (Age 61)
  • Charles R. Kummeth, President, Chief Executive Officer, Director (Age 57)
  • James T. Hippel, Chief Financial Officer, Senior Vice President (Age 45)
  • Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary (Age 58)
  • David Eansor, Senior Vice President - Biotechnology (Age 54)
  • Robert Gavin, Senior Vice President-Protein Platforms (Age 48)
  • Kevin S. Gould, Senior Vice President-Clinical Controls (Age 52)
  • Joseph D. Keegan Ph.D., Director (Age 62)
  • Alpna Seth, Director (Age 54)
  • Charles A. Dinarello M.D., Independent Director (Age 74)

Who owns BIO-TECHNE stock?

BIO-TECHNE's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Brown Capital Management LLC (5.41%), Atlanta Capital Management Co. L L C (5.18%), Bamco Inc. NY (4.05%), Jackson Square Partners LLC (2.49%), Royce & Associates LP (1.66%) and Riverbridge Partners LLC (1.41%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.

Who sold BIO-TECHNE stock? Who is selling BIO-TECHNE stock?

BIO-TECHNE's stock was sold by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, American Century Companies Inc., Segall Bryant & Hamill LLC, Brown Capital Management LLC, Millennium Management LLC, Schroder Investment Management Group, Royce & Associates LP and Candriam Luxembourg S.C.A.. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.

Who bought BIO-TECHNE stock? Who is buying BIO-TECHNE stock?

BIO-TECHNE's stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Amundi Pioneer Asset Management Inc., Jackson Square Partners LLC, First Trust Advisors LP, Conestoga Capital Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for BIO-TECHNE.

How do I buy BIO-TECHNE stock?

Shares of BIO-TECHNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of BIO-TECHNE stock can currently be purchased for approximately $141.99.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $5.23 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.05 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for BIO-TECHNE (TECH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BIO-TECHNE (NASDAQ:TECH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.672.502.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $144.25$138.00$130.00$126.33
Price Target Upside: 4.71% upside1.44% downside5.03% upside11.22% upside

BIO-TECHNE (NASDAQ:TECH) Consensus Price Target History

Price Target History for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ:TECH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Craig HallumReiterated RatingBuy$140.00 -> $160.00MediumView Rating Details
2/7/2018Robert W. BairdBoost Price TargetOutperform -> Outperform$154.00 -> $157.00MediumView Rating Details
12/5/2017Leerink SwannReiterated RatingBuyMediumView Rating Details
10/31/2017Deutsche BankSet Price TargetBuy$145.00N/AView Rating Details
10/24/2017CitigroupReiterated RatingBuy$125.00 -> $115.00N/AView Rating Details
7/13/2017Wells Fargo & CoInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

BIO-TECHNE (NASDAQ:TECH) Earnings History and Estimates Chart

Earnings by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ TECH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$1.12N/AView Earnings Details
2/6/2018Q2 2018$0.92$1.02$145.93 million$154.15 millionViewListenView Earnings Details
10/31/2017Q1 2018$0.82$0.90$142.37 million$144.61 millionViewN/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
10/26/2010Q1 2011$0.73$0.71ViewN/AView Earnings Details
8/3/2010Q4 2010$0.71$0.69ViewN/AView Earnings Details
5/4/2010Q3 2010$0.79$0.87ViewN/AView Earnings Details
2/2/2010Q2 2010$0.68$0.66ViewN/AView Earnings Details
10/28/2009Q1 2010$0.70$0.72ViewN/AView Earnings Details
8/4/2009Q4 2009$0.69$0.68ViewN/AView Earnings Details
4/28/2009Q3 2009$0.72$0.74ViewN/AView Earnings Details
2/3/2009Q2 2009$0.64$0.62ViewN/AView Earnings Details
10/22/2008Q1 2009$0.66$0.74ViewN/AView Earnings Details
8/5/2008Q4 2008$0.67$0.70ViewN/AView Earnings Details
4/29/2008Q3 2008$0.66$0.76ViewN/AView Earnings Details
1/29/2008Q2 2008$0.54$0.60ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BIO-TECHNE (NASDAQ:TECH) Earnings Estimates

2018 EPS Consensus Estimate: $3.92
2019 EPS Consensus Estimate: $4.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.88$0.88$0.88
Q2 20182$0.84$0.88$0.86
Q3 20182$0.96$1.09$1.03
Q4 20182$1.09$1.21$1.15
Q1 20192$0.89$1.02$0.96
Q2 20192$0.92$1.11$1.02
Q3 20192$1.04$1.24$1.14
Q4 20192$1.18$1.33$1.26
(Earnings estimates data provided by Zacks Investment Research)

Dividends

BIO-TECHNE (NASDAQ:TECH) Dividend Information

Next Dividend:3/2/2018
Annual Dividend:$1.28
Dividend Yield:0.90%
Payout Ratio:41.97% (Trailing 12 Months of Earnings)
32.00% (Based on This Year's Estimates)
27.95% (Based on Next Year's Estimates)
Dividend Payments by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ:TECH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2018quarterly$0.320.94%2/15/20182/16/20183/2/2018
10/31/2017Quarterly$0.321%11/9/201711/10/201711/24/2017
8/9/2017Quarterly$0.321.1%8/16/20178/18/20179/1/2017
5/2/2017quarterly$0.321.15%5/17/20175/19/20176/2/2017
2/7/2017quarterly$0.321.27%2/15/20172/17/20173/3/2017
11/1/2016Quarterly$0.3211/9/201611/14/201611/28/2016
8/17/2016quarterly$0.328/25/20168/29/20169/12/2016
5/3/2016quarterly$0.321.27%5/11/20165/13/20165/27/2016
2/2/2016quarterly$0.321.48%2/10/20162/12/20162/26/2016
10/29/2015quarterly$0.321.45%11/10/201511/13/201511/27/2015
8/6/2015quarterly$0.321.18%8/13/20158/17/20158/28/2015
5/5/2015quarterly$0.321.31%5/11/20155/15/20155/29/2015
2/3/2015quarterly$0.321.4%2/11/20152/13/20152/27/2015
10/30/2014quarterly$0.321.41%11/6/201411/10/201411/24/2014
8/11/2014quarterly$0.311.31%8/19/20148/21/20148/29/2014
4/28/2014quarterly$0.311.37%5/7/20145/9/20145/23/2014
2/4/2014quarterly$0.311.48%2/12/20142/14/20142/28/2014
10/31/2013quarterly$0.311.4%11/7/201311/12/201311/25/2013
8/6/2013quarterly$0.301.62%8/14/20138/16/20138/31/2013
4/30/2013quarterly$0.301.86%5/8/20135/10/20135/24/2013
2/5/2013quarterly$0.301.74%2/13/20132/15/20133/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

BIO-TECHNE (NASDAQ TECH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 98.00%
Insider Trades by Quarter for BIO-TECHNE (NASDAQ:TECH)
Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

BIO-TECHNE (NASDAQ TECH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Charles A DinarelloDirectorSell5,000$136.06$680,300.00View SEC Filing  
11/1/2017Robert V BaumgartnerDirectorSell5,000$130.18$650,900.0012,712View SEC Filing  
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.001,970View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07914View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.002,070View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.002,170View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.002,270View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.0012,473View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.006,973View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.003,429View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.003,529View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.003,829View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.001,973View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.004,029View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.003,315View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.001,359View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.398,446View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.309,592View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.003,615View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.003,715View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.003,815View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.006,559View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.003,915View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.004,315View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.004,415View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.004,515View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.001,000View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.001,000View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.001,000View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.001,000View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.004,000View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BIO-TECHNE (NASDAQ TECH) News Headlines

Source:
DateHeadline
$163.18 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter$163.18 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter
www.americanbankingnews.com - February 22 at 5:46 AM
BIO-TECHNE Corp (TECH) Expected to Announce Earnings of $1.14 Per ShareBIO-TECHNE Corp (TECH) Expected to Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - February 20 at 4:08 PM
Bio-Techne Corporation (TECH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowBio-Techne Corporation (TECH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 17 at 8:48 AM
BIO-TECHNE Corp (TECH) Director Sells $680,300.00 in StockBIO-TECHNE Corp (TECH) Director Sells $680,300.00 in Stock
www.americanbankingnews.com - February 15 at 9:28 PM
Blog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell CarcinomaBlog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell Carcinoma
finance.yahoo.com - February 14 at 9:19 AM
BIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by BrokeragesBIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 11:04 AM
BIO-TECHNE (TECH) Lifted to Buy at Zacks Investment ResearchBIO-TECHNE (TECH) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - February 10 at 1:30 PM
BIO-TECHNE Corp (TECH) to Post FY2018 Earnings of $4.07 Per Share, Leerink Swann ForecastsBIO-TECHNE Corp (TECH) to Post FY2018 Earnings of $4.07 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - February 9 at 12:28 PM
Q3 2018 Earnings Forecast for BIO-TECHNE Corp (TECH) Issued By Leerink SwannQ3 2018 Earnings Forecast for BIO-TECHNE Corp (TECH) Issued By Leerink Swann
www.americanbankingnews.com - February 8 at 11:37 AM
BIO-TECHNE Corp (TECH) Announces $0.32 Quarterly DividendBIO-TECHNE Corp (TECH) Announces $0.32 Quarterly Dividend
www.americanbankingnews.com - February 8 at 12:12 AM
BIO-TECHNEs (TECH) "Buy" Rating Reaffirmed at Craig HallumBIO-TECHNE's (TECH) "Buy" Rating Reaffirmed at Craig Hallum
www.americanbankingnews.com - February 7 at 1:24 PM
Bio-Techne Named "Researchers Choice" by CiteAbBio-Techne Named "Researchers' Choice" by CiteAb
finance.yahoo.com - February 7 at 9:23 AM
BIO-TECHNEs (TECH) "Buy" Rating Reiterated at Robert W. BairdBIO-TECHNE's (TECH) "Buy" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - February 7 at 8:36 AM
What does Bio-Techne Corporation’s (NASDAQ:TECH) Balance Sheet Tell Us About Its Future?What does Bio-Techne Corporation’s (NASDAQ:TECH) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - February 6 at 4:16 PM
BIO-TECHNE (TECH) Issues  Earnings Results, Beats Estimates By $0.17 EPSBIO-TECHNE (TECH) Issues Earnings Results, Beats Estimates By $0.17 EPS
www.americanbankingnews.com - February 6 at 10:02 AM
Bio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick FactsBio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick Facts
www.nasdaq.com - February 6 at 9:18 AM
BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29
www.reuters.com - February 6 at 9:18 AM
Bio-Techne Releases Second Quarter Fiscal 2018 ResultsBio-Techne Releases Second Quarter Fiscal 2018 Results
finance.yahoo.com - February 6 at 9:18 AM
Bio-Techne Corporation to Host Earnings CallBio-Techne Corporation to Host Earnings Call
finance.yahoo.com - February 6 at 9:18 AM
Bio-Techne To Present At The Leerink Partners 7th Annual Global Healthcare ConferenceBio-Techne To Present At The Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 5 at 9:18 AM
BIO-TECHNE (TECH) Cut to "Hold" at Zacks Investment ResearchBIO-TECHNE (TECH) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 3 at 2:44 PM
BIO-TECHNE Corp (TECH) Expected to Post Earnings of $0.92 Per ShareBIO-TECHNE Corp (TECH) Expected to Post Earnings of $0.92 Per Share
www.americanbankingnews.com - February 3 at 1:28 PM
Bio-Technes Ella™ Added to BioAgilytix Portfolio of Industry-Leading Immunoassay PlatformsBio-Techne's Ella™ Added to BioAgilytix Portfolio of Industry-Leading Immunoassay Platforms
www.prnewswire.com - January 30 at 5:55 PM
BIO-TECHNE (TECH) to Release Quarterly Earnings on TuesdayBIO-TECHNE (TECH) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 2:38 AM
BIO-TECHNE (TECH) Raised to Buy at Zacks Investment ResearchBIO-TECHNE (TECH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - January 20 at 4:08 PM
BIO-TECHNE Corp (TECH) Expected to Post Quarterly Sales of $145.90 MillionBIO-TECHNE Corp (TECH) Expected to Post Quarterly Sales of $145.90 Million
www.americanbankingnews.com - January 19 at 10:34 AM
BIO-TECHNE Corp (TECH) Given Consensus Recommendation of "Buy" by BrokeragesBIO-TECHNE Corp (TECH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 19 at 8:02 AM
Robert W. Baird Reaffirms "Buy" Rating for BIO-TECHNE (TECH)Robert W. Baird Reaffirms "Buy" Rating for BIO-TECHNE (TECH)
www.americanbankingnews.com - January 19 at 12:58 AM
Q3 2018 EPS Estimates for BIO-TECHNE Corp Increased by Leerink Swann (TECH)Q3 2018 EPS Estimates for BIO-TECHNE Corp Increased by Leerink Swann (TECH)
www.americanbankingnews.com - January 18 at 12:26 PM
BIO-TECHNE Corp (TECH) to Post Q2 2018 Earnings of $0.88 Per Share, Leerink Swann ForecastsBIO-TECHNE Corp (TECH) to Post Q2 2018 Earnings of $0.88 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 17 at 2:04 PM
Advanced Immunolabeling Reagents and Tools from Vector Laboratories Now from Bio-TechneAdvanced Immunolabeling Reagents and Tools from Vector Laboratories Now from Bio-Techne
finance.yahoo.com - January 15 at 10:55 AM
BRIEF-Bio-Techne Acquires Atlanta Biologicals IncBRIEF-Bio-Techne Acquires Atlanta Biologicals Inc
www.reuters.com - January 3 at 3:51 PM
Bio-Techne acquires Atlanta Biologicals to shore up tissue offeringsBio-Techne acquires Atlanta Biologicals to shore up tissue offerings
seekingalpha.com - January 2 at 10:56 PM
Bio-Techne Acquires Atlanta Biologicals Inc.Bio-Techne Acquires Atlanta Biologicals Inc.
finance.yahoo.com - January 2 at 9:19 PM
BIO-TECHNE Corp (TECH) Expected to Announce Earnings of $0.92 Per ShareBIO-TECHNE Corp (TECH) Expected to Announce Earnings of $0.92 Per Share
www.americanbankingnews.com - December 31 at 9:32 PM
Bio-Techne To Present At The 36th Annual J.P. Morgan Healthcare ConferenceBio-Techne To Present At The 36th Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - December 28 at 8:28 AM
BIO-TECHNE (TECH) Downgraded by Zacks Investment ResearchBIO-TECHNE (TECH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 27 at 7:16 AM
BIO-TECHNE Corp (TECH) Given Consensus Rating of "Buy" by BrokeragesBIO-TECHNE Corp (TECH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 25 at 8:06 AM
Zacks Investment Research Upgrades BIO-TECHNE (TECH) to "Buy"Zacks Investment Research Upgrades BIO-TECHNE (TECH) to "Buy"
www.americanbankingnews.com - December 20 at 5:56 PM
Zacks Investment Research Downgrades BIO-TECHNE (TECH) to HoldZacks Investment Research Downgrades BIO-TECHNE (TECH) to Hold
www.americanbankingnews.com - December 19 at 9:46 AM
BIO-TECHNE Corp (TECH) Expected to Announce Quarterly Sales of $145.90 MillionBIO-TECHNE Corp (TECH) Expected to Announce Quarterly Sales of $145.90 Million
www.americanbankingnews.com - December 17 at 2:48 PM
ETFs with exposure to Bio-Techne Corp. : December 15, 2017ETFs with exposure to Bio-Techne Corp. : December 15, 2017
finance.yahoo.com - December 15 at 3:58 PM
$0.92 Earnings Per Share Expected for BIO-TECHNE Corp (TECH) This Quarter$0.92 Earnings Per Share Expected for BIO-TECHNE Corp (TECH) This Quarter
www.americanbankingnews.com - December 15 at 1:28 AM
Bio-Techne (TECH) Stock Rating Lowered by BidaskClubBio-Techne (TECH) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 11 at 12:14 AM
Bio-Technes (TECH) "Buy" Rating Reaffirmed at Leerink SwannBio-Techne's (TECH) "Buy" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - December 5 at 10:34 AM
TECH Crosses Above Average Analyst TargetTECH Crosses Above Average Analyst Target
www.nasdaq.com - December 1 at 6:21 PM
Bio-Techne Corp (TECH) Given Average Rating of "Buy" by AnalystsBio-Techne Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 30 at 8:54 AM
Bio-Technes RNAscope® Technology Enabling Robust Gene Expression and Biomarker Analysis Advances Wide-ranging Research with over 1000 PublicationsBio-Techne's RNAscope® Technology Enabling Robust Gene Expression and Biomarker Analysis Advances Wide-ranging Research with over 1000 Publications
finance.yahoo.com - November 28 at 11:08 AM
$145.90 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter$145.90 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter
www.americanbankingnews.com - November 28 at 2:52 AM
ETFs with exposure to Bio-Techne Corp. : November 27, 2017ETFs with exposure to Bio-Techne Corp. : November 27, 2017
finance.yahoo.com - November 27 at 4:03 PM

SEC Filings

BIO-TECHNE (NASDAQ:TECH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BIO-TECHNE (NASDAQ:TECH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BIO-TECHNE (NASDAQ TECH) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.